U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H31NO2.ClH
Molecular Weight 353.927
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DROFENINE HYDROCHLORIDE

SMILES

Cl.CCN(CC)CCOC(=O)C(C1CCCCC1)C2=CC=CC=C2

InChI

InChIKey=WIELVDXKOYPANK-UHFFFAOYSA-N
InChI=1S/C20H31NO2.ClH/c1-3-21(4-2)15-16-23-20(22)19(17-11-7-5-8-12-17)18-13-9-6-10-14-18;/h5,7-8,11-12,18-19H,3-4,6,9-10,13-16H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C20H31NO2
Molecular Weight 317.4656
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Drofenine, product name Spasmo-Cibalgin (Novartis, Oman), is an antispasmodic/anticholinergic agent used for relaxing smooth muscle, treating dysmenorrhea, and relieving pain in the gastrointestinal tract, biliary passages, and urogenital tract. The possible therapeutic effect of drofenine is proposed by its activation of transient receptor potential vanilloid-3 (TRPV3), a member of the TRPV subfamily of TRP ion channels.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q8NET8
Gene ID: 162514.0
Gene Symbol: TRPV3
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Spasmo Cibalgin

Approved Use

Unknown
Primary
Spasmo Cibalgin

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Simultaneous determination of hydrochloride salts of adiphenine, diphenhydramine, ethyldiphenacetate, drofenine and promazine by ion-pair HPLC.
1983 Aug
Inhibition effects of benactyzine and drofenine on human serum butyrylcholinesterase.
2001 Feb 1
Drofenine: A 2-APB Analogue with Greater Selectivity for Human TRPV3.
2014 Oct

Sample Use Guides

tablet
Route of Administration: Oral
Drofenine, was selective for TRPV3 in that activation of TRPA1, M8, V1, V2, and V4, which are known to be activated by the TRPV3 agonists 2-APB and/or carvacrol, was not observed at concentrations up to 1 mmol/L. A detectable change in TRPV3 activity was observed at concentrations as low as 30 μmol/L and increased in a concentration-dependent manner. At concentrations greater than 500 μmol/L, calcium flux exhibited some evidence of TRPV3 independence based on small and comparable responses in both native HEK-293 cells and other TRP channel overexpressing cell lines. The maximum change in cytosolic calcium (ΔF) for drofenine (EC50 = 207 μmol/L) was comparable to the known TRPV3 agonists 2-APB (EC50 = 78 μmol/L) and carvacrol (EC50 = 438 μmol/L).
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:00:58 GMT 2023
Edited
by admin
on Fri Dec 15 17:00:58 GMT 2023
Record UNII
MVB31OPW05
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DROFENINE HYDROCHLORIDE
MART.   MI   WHO-DD  
Common Name English
NSC-42559
Code English
CYCLOADIPHENINE HYDROCHLORIDE
Common Name English
2-(DIETHYLAMINO)ETHYL 2-CYCLOHEXYL-2-PHENYLACETATE HYDROCHLORIDE
Common Name English
2-(DIETHYLAMINO)ETHYL .ALPHA.-PHENYLCYCLOHEXANEACETATE HYDROCHLORIDE
Systematic Name English
DROFENINE HCL
Common Name English
DROFENINE HYDROCHLORIDE [MART.]
Common Name English
DROFENINE HYDROCHLORIDE [MI]
Common Name English
IT-19
Code English
2-(DIETHYLAMINO)ETHYL .ALPHA.-CYCLOHEXYLBENZENEACETATE HYDROCHLORIDE
Common Name English
Drofenine hydrochloride [WHO-DD]
Common Name English
Code System Code Type Description
RXCUI
289372
Created by admin on Fri Dec 15 17:00:59 GMT 2023 , Edited by admin on Fri Dec 15 17:00:59 GMT 2023
PRIMARY RxNorm
MERCK INDEX
m4764
Created by admin on Fri Dec 15 17:00:59 GMT 2023 , Edited by admin on Fri Dec 15 17:00:59 GMT 2023
PRIMARY Merck Index
NSC
42559
Created by admin on Fri Dec 15 17:00:59 GMT 2023 , Edited by admin on Fri Dec 15 17:00:59 GMT 2023
PRIMARY
FDA UNII
MVB31OPW05
Created by admin on Fri Dec 15 17:00:59 GMT 2023 , Edited by admin on Fri Dec 15 17:00:59 GMT 2023
PRIMARY
EPA CompTox
DTXSID3045859
Created by admin on Fri Dec 15 17:00:59 GMT 2023 , Edited by admin on Fri Dec 15 17:00:59 GMT 2023
PRIMARY
PUBCHEM
92806
Created by admin on Fri Dec 15 17:00:59 GMT 2023 , Edited by admin on Fri Dec 15 17:00:59 GMT 2023
PRIMARY
SMS_ID
100000087736
Created by admin on Fri Dec 15 17:00:59 GMT 2023 , Edited by admin on Fri Dec 15 17:00:59 GMT 2023
PRIMARY
ECHA (EC/EINECS)
208-954-1
Created by admin on Fri Dec 15 17:00:59 GMT 2023 , Edited by admin on Fri Dec 15 17:00:59 GMT 2023
PRIMARY
CAS
548-66-3
Created by admin on Fri Dec 15 17:00:59 GMT 2023 , Edited by admin on Fri Dec 15 17:00:59 GMT 2023
PRIMARY
MESH
C007183
Created by admin on Fri Dec 15 17:00:59 GMT 2023 , Edited by admin on Fri Dec 15 17:00:59 GMT 2023
PRIMARY
EVMPD
SUB01838MIG
Created by admin on Fri Dec 15 17:00:59 GMT 2023 , Edited by admin on Fri Dec 15 17:00:59 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
Related Record Type Details
ACTIVE MOIETY